For couples undergoing assisted reproductive technology (ART), the
financial burden of treatment is a major concern alongside clinical outcomes. As
a highly purified urinary follicle-stimulating hormone (FSH) preparation,
Urofollitropin plays a pivotal role in ovulation induction, and Urofollitropin
price has become a key consideration for both clinicians and patients when
formulating treatment plans. Unlike expensive recombinant FSH products,
Urofollitropin offers a cost-effective alternative without compromising
therapeutic efficacy, making it a preferred choice in resource-conscious ART
practices worldwide.
Several key factors influence Urofollitropin price, with product
specification and production technology being the most prominent. Urofollitropin
is commonly available in 75 IU and 150 IU formulations1, and
the price typically scales with the dosage, allowing for flexible selection
based on individual ovarian response. Additionally, advanced purification
technologies contribute to price variations—highly purified Urofollitropin with
reduced protein impurities ensures better safety and efficacy, which is
reflected in its pricing. Compared to imported recombinant FSH products that can
cost up to $240 per vial, domestically produced Urofollitropin offers
significant cost advantages, with prices approximately 30-40% lower while
maintaining comparable clinical outcomes.
The cost-effectiveness of Urofollitropin is further validated by its
clinical performance in diverse ART protocols. In controlled ovarian
hyperstimulation (COH), Urofollitropin effectively stimulates follicular
development, with clinical pregnancy rates similar to those of recombinant FSH
in patients with normal ovarian reserve. A retrospective study involving 520 ART
cycles found that the cumulative pregnancy rate in the Urofollitropin group was
42.3%, comparable to the 43.1% in the recombinant FSH group, while the total
medication cost per cycle was reduced by 35%. This balance of efficacy and
affordability is particularly valuable for patients requiring multiple ART
cycles, as it significantly lowers the overall financial burden without
sacrificing treatment quality.
Another critical aspect affecting Urofollitropin price perception is its
role in personalized treatment strategies, which helps avoid unnecessary costs.
Clinicians tailor Urofollitropin dosage and administration duration based on
individual factors such as age, ovarian reserve, and previous treatment history.
For example, patients with mild ovarian insufficiency may require lower dosages,
while those undergoing the GnRH antagonist protocol may have optimized treatment
courses that reduce the total number of vials used. This personalized approach
not only improves treatment success rates but also ensures that patients only
pay for the necessary medication, enhancing the overall value of Urofollitropin
in ART.
As a professional pharmaceutical manufacturer dedicated to reproductive
health, Kangyuan is committed to providing high-quality Urofollitropin products
at competitive prices. Our Urofollitropin adheres to strict international
quality control standards, utilizing advanced purification technologies to
ensure high purity and consistent efficacy. We offer flexible formulations (75
IU and 150 IU) to meet diverse clinical needs, and our streamlined production
processes enable us to maintain favorable Urofollitropin price points without
compromising quality. If you are a healthcare provider seeking cost-effective
ovulation induction solutions, or an infertile couple exploring affordable ART
options, please contact Kangyuan’s professional team. We will provide tailored
product information and clinical advice to help you balance treatment efficacy
and financial sustainability, supporting your journey towards parenthood.